Capricor Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-81.99	-40.47	-22.29	-29.02	-20.02	-13.66
Depreciation & Amortization	1.76	1.43	1.07	0.53	0.25	0.14
Stock-Based Compensation	15.81	9.77	7.39	4.46	2.97	1.95
Other Adjustments	0.35	0.11	0.01	0.03	-0.31	-
Change in Receivables	0.35	0	-9.82	-0.16	-0.39	0.09
Changes in Accounts Payable	5.48	1.94	1.33	1.21	0.99	1.83
Changes in Unearned Revenue	-1.13	-12.27	-3.18	27.45	-	-
Changes in Other Operating Activities	-1.54	-0.51	-0.1	0.41	-0.29	-0.41
Operating Cash Flow	-61.04	-40	-25.6	4.92	-16.81	-10.05
Capital Expenditures	-6.82	-1.54	-2.05	-3.36	-1.2	-0.55
Purchases of Investments	-275.76	-208.44	-97.44	-114.22	-	-6.13
Proceeds from Sale of Investments	214.1	93.8	104.6	82.51	-	12.12
Investing Cash Flow	-68.99	-116.18	5.11	-35.07	-1.2	5.44
Long-Term Debt Issued	-	-	-	-	-	0.32
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	0.32
Issuance of Common Stock	81.16	152.77	25.58	4.87	20.23	33.06
Net Common Stock Issued (Repurchased)	81.16	152.77	25.58	4.87	20.23	33.06
Financing Cash Flow	81.16	152.77	25.58	4.87	20.23	33.38
Net Cash Flow	8.52	-3.41	5.09	-25.28	2.22	28.77
Free Cash Flow	-67.86	-41.53	-27.64	1.56	-18.01	-10.6
FCF Margin	-609.67%	-186.50%	-109.79%	61.02%	-7352.29%	-3417.38%
Free Cash Flow Per Share	-1.49	-1.18	-1.03	0.06	-0.78	-0.68
Levered Free Cash Flow	-84.24	-51.42	-25.22	-2.78	-20.27	-12.32
Unlevered Free Cash Flow	-88.94	-53.51	-27.01	-3.46	-21.19	-12.68

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q